{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-055935","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.004061+00:00","generated_at":"2026-06-05T05:36:11.912774+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics raises $350M in oversubscribed private placement of 8.33M shares at $42/sh","bullets":["Private placement of 8,333,334 common shares at $42.00/share raises ~$350M gross proceeds.","Oversubscribed placement includes new and existing investors like Adage Capital, Driehaus, EcoR1, Janus Henderson.","Net proceeds to fund R&D of clinical-stage candidates, working capital, and general corporate purposes.","Closing expected March 1, 2024; resale registration statement to be filed within 40 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-055935","json":"https://secwatch.observer/filing/0001193125-24-055935.json","markdown":"https://secwatch.observer/filing/0001193125-24-055935.md","text":"https://secwatch.observer/filing/0001193125-24-055935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/0001193125-24-055935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/d773342d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:36:11.912774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4d3b000e29583f7dfbb9e10eb6dc514ed82efb6","claim":"Crinetics Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at aggregate gross proceeds from the Private Placement of approximately $350 million (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 8,333,334 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $ 42.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524055935/0001193125-24-055935-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors named therein"},{"label":"Value","value":"aggregate gross proceeds from the Private Placement of approximately $350 million"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}